Urologic complications of diabetes

Diabetes Care

Volumn 28, Issue 1, 2005, Pages 177-185

  Brown, Jeanette S ^a   Wessells, Hunter ^b   Chancellor, Michael B ^c   Howards, Stuart S ^d   Stamm, Walter E ^b   Stapleton, Ann E ^b   Steers, William D ^d   Van Den Eeden, Stephen K ^e   McVary, Kevin T ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e DIVISION OF RESEARCH   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOPHILIN; INSULIN; ORAL ANTIDIABETIC AGENT; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE; VASCULOTROPIN;

AROUSAL; ASYMPTOMATIC BACTERIURIA; BLADDER; BLADDER DYSFUNCTION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIABETES MELLITUS; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; GENE THERAPY; HUMAN; LIBIDO DISORDER; MALE SEXUAL DYSFUNCTION; MUSCLE TRAINING; NOCTURIA; NONHUMAN; ORGASM DISORDER; PATHOPHYSIOLOGY; PREVALENCE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; REVIEW; SEXUAL DYSFUNCTION; STRESS INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE;

DIABETES COMPLICATIONS; FEMALE; HUMANS; IMPOTENCE; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; URINARY BLADDER DISEASES; UROLOGIC DISEASES;

EID: 11844252545     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.1.177     Document Type: Review

References (118)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524, 1998
2. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, Lavezzari M, Landoni M, Parazzini F: Erectile dysfunction in type 1 and type 2 diabetics in Italy: on behalf of Gruppo ltaliano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 29:524-531, 2000
3. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: prevalence and predictors. JAMA 281;537-544, 1999
4. Goldman HB, Appell RA: Voiding dysfunction in women with diabetes mellitus. Int Urogynecol J Pelvic Floor Dysfunct 10:130-133, 1999
5. Kaplan SA, Te AE, Blaivas JG: Urodynamic findings in patients with diabetic cystopathy. J Urol 153:342-344, 1995
6. Frimodt-Moller C: Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med 92:318-321, 1980
7. Menendez V, Cofan F, Talbot-Wright R, Ricart MJ, Gutierrez R, Carretero P: Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease (see comments). J Urol 155:2001-2004, 1996
8. Perry S, Shaw C, Assassa P, Dallosso H, Williams K, Brittain KR, Mensah F, Smith N, Clarke M, Jagger C, Mayne C, Castleden CM, Jones J, McGrother C: An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study: Leicestershire MRC Incontinence Study Team. J Public Health Med 22:427-434, 2000
9. Wetle T, Scherr P, Branch LG, Resnick NM, Harris T, Evans D, Taylor JO: Difficulty with holding urine among older persons in a geographically defined community: prevalence and correlates. J Am Geriatr Soc 43:349-355, 1995
10. Brown J, Grady D, Ouslander J, Herzog A, Varner R, Posner S: Prevalence of urinary incontinence and associated risk factors in postmenopausal women: Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 94:66-70, 1999
11. Sampselle CM, Harlow SD, Skurnick J, Brubaker L, Bondarenko I: Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. Obstet Gynecol 100:1230-1238, 2002
12. Lifford K, Curhan G, Grodstein F: Type 2 diabetes and risk of developing urinary incontinence in the Nurses' Health Study (Abstract). In Urologic Complications of Diabetes. Bethesda, MD, National Institutes of Health, 2003, p. 31
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
14. Brown JS, Barrett-Connor E, Nyberg LM, JW K, TJ O, Ma Y, Vittinghoff E: Incontinence in women with impaired glucose tolerance: results of the Diabetes Prevention Program (Abstract). J Urol 171:325-326, 2004
15. Subak LL, Johnson C, Whitcomb E, Boban D, Saxton J, Brown JS: Does weight loss improve incontinence in moderately obese women? Int J Urogyn 13:40-43, 2002
16. Jackson RA, Vittinghoff E, Kanaya AM, Resnick HE, Kritchevsky S, Miles T, Simonsick E, Brown JS, for the Health, Aging and Body Composition (Health ABC) Research Group: Urinary incontinence in elderly women: finding from the Health, Aging, and Body Composition Study. Obstet Gynecol 104:301-307, 2004
17. Holroyd-Leduc JM, Straus SE: Management of urinary incontinence in women: scientific review. JAMA 291:986-995, 2004
18. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, Kiemeney L, Lee C: The prevalence of lower urinary tract symptoms in men and women in four centres: the UrEpik study. BJU Int 92:409-414, 2003
19. Blaivas JG: Cause and effect of lower urinary tract symptoms (Editorial). J Urol 168:1464, 2002
20. Klein BE, Klein R, Lee KE, Bruskewitz RC: Correlates of urinary symptom scores in men. Am J Public Health 89:1745-1748, 1999
21. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, James SA, Cooney KA, Doerr KM, Montie JE, Schottenfeld D: Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 157:906-914, 2003
22. Van Den Eeden SK, Enger S, Caan BJ, Quesenberry CPJ, Sternfeld B, Ferrara A, Loo R, Rowell S, Habel LA: Urologic conditions and diabetes in the California Men's Health Study (Abstract). In Urologic Complications of Diabetes. Bethesda, Maryland, National Institutes of Health, 2003, p. 49
23. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M: Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 163:1725-1729 2000
24. Bourke JB, Griffin JP: Diabetes mellitus and prostatic hyperplasia. Br Med J 4:832-833, 1968
25. Glynn RJ, Campion EW, Bouchard GR, Silbert JE: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 121:78-90, 1985
26. Sidney S, Quesenberry C Jr, Sadler MC, Lydick EG, Guess HA, Cattolica EV: Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 38:13-19, 1991
27. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54:935-944, 2001
28. Burke JP, Jacobson DJ, Roberts RO, Girman CJ, Lieber MM, Jacobsen SJ: BPH progression and diabetes mellitus in Olmsted County, Minnesota (Poster Abstract). In Urologic Complications of Diabetes. Bethesda, Maryland, National Institutes of Health, 2003, p. 61
29. Kanda M, Eto K, Tanabe N, Sugiyama A, Hashimoto K, Ueno A: Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes. Jpn J Pharmacol 73:221-228, 1997
30. Longhurst PA, Belis JA: Abnormalities of rat bladder contractility in streptozotocin-induced diabetes mellitus. J Pharmacol Exp Ther 238:773-777, 1986
31. Tong YC, Cheng JT, Wan WC: Effects of Ba-Wei-Die-Huang-Wan on the cholinergic function and protein expression of M2 muscarinic receptor of the urinary bladder in diabetic rats. Neurosci Lett 330:21-24, 2002
32. Kubota Y, Nakahara T, Mitani A, Maruko T, Sakamoto K, Ishii K: Augmentation of rat urinary bladder relaxation mediated by beta1-adrenoceptors in experimental diabetes. Eur J Pharmacol 467:191-195, 2003
33. Waring JV, Wendt IR: Effects of streptozotocin-induced diabetes mellitus on intracellular calcium and contraction of longitudinal smooth muscle from rat urinary bladder. J Urol 163:323-330, 2000
34. Bezuijen MW, Levendusky MC, Longhurst PA: Functional response of bladder strips from streptozotocin diabetic rats depends on bladder mass. J Urol 169:2397-2401, 2003
35. Hashitani H, Suzuki H: Altered electrical properties of bladder smooth muscle in streptozotocin-induced diabetic rats. Br J Urol 77:798-804, 1996
36. Sasaki K, Chancellor MB, Phelan MW, Yokoyama T, Eraser MO, Seki S, Kubo K, Kumon H, Groat WC, Yoshimura N: Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J Urol 168:1259-1264, 2002
37. Pitre DA, Ma T, Wallace LJ, Bauer JA: Time-dependent urinary bladder remodeling in the streptozotocin-induced diabetic rat model. Acta Diabetol 39:23-27, 2002
38. Enzlin P, Mathieu C, Vanderschueren D, Demyttenaere K: Diabetes mellitus and female sexuality: a review of 25 years' research. Diabet Med 15:809-815, 1998
39. Webster L: Management of sexual problems in diabetic patients. Br J Hosp Med 51:465-468, 1994
40. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ: Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 19: 135-141, 1996
41. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentim M, Nicolucci A: Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care 25:284-291, 2002
42. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF: Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 26:1093-1099, 2003
43. Klein BE, Klein R: Ten year incidence of self-reported erectile dysfunction in people with long-term type 1 diabetes. J Diabetes Complications. In press
44. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB: Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163:460-463, 2000
45. Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 163:788-791, 2000
46. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, Landoni M, Parazzini F: Erectile dysfunction in diabetic subjects in Italy: Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 21:1973-1977, 1998
47. Bortolotti A, Fedele D, Chatenoud L, Colli E, Coscelli C, Landoni M, Lavezzari M, Santeusanio F, Parazzini F: Cigarette smoking: a risk factor for erectile dysfunction in diabetics. Eur Urol 40:392-396 (discussion 397), 2001
48. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB: Sexual function in men older than 50 years of age: results from the Health Professionals Follow-Up Study. Ann Intern Med 139:161-168, 2003
49. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 25:2159-2164, 2002
50. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T: Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26:777-783, 2003
51. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med 338:1397-1404, 1998
52. Lepore G, Nosari I: Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. Diabetes Care 24:409-411, 2001
53. Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, Krane RJ, Udelson D, Saenz de Tejada I, Moreland RB: Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol 156:1320-1329, 1996
54. Carson CC, Mulcahy JJ, Govier FE: Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study: AMS 700CX Study Group J Urol 164:376-380, 2000
55. Lin CS, Lau A, Tu R, Lue TF: Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268:628-635, 2000
56. Mills TM, Chitaley K, Lewis RW, Webb RC: Nitric oxide inhibits RhoA/Rho-kinase signaling to cause penile erection. Eur J Pharmacol 439:173-174, 2002
57. Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex BH, Hagen PO, Donatucci CF: Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol 165:1310-1315, 2001
58. Burnett AL, Becker RE: Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol 171:495-500, 2004
59. Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J, Gonzalez-Cadavid NF: Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 67:20-28, 2002
60. Christ GJ, Rehman J, Day N, Salkoff L, Valcic M, Melman A, Geliebter J: Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 275:H600-H608, 1998
61. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326:90-94, 1992
62. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, Polak J, Wang RZ, Ferguson K, Block C, Haas C: Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 50:1016-1026, 1997
63. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC: Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 283:923-927, 2001
64. Autieri MV, Melman A, Christ GJ: Identification of a down-regulated mRNA transcript in corpus cavernosum from diabetic patients with erectile dysfunction. Int J Impot Res 8:69-73, 1996
65. Bax G, Marin N, Piarulli F, Lamonica M, Bellio F, Fedele D: Rigiscan evaluation of specific nervous impairment in patients with diabetes and erectile disorders. Diabetes Care 21:1159-1161, 1998
66. Vardi Y, Sprecher E, Kanter Y, Livne PM, Hemli JA, Yarnitsky D: Polyneuropathy in impotence. Int J Impot Res 8:65-68, 1996
67. Wellmer A, Sharief MK, Knowles CH, Misra VP, Kopelman P, Ralph D, Anand P: Quantitative sensory and autonomie testing in male diabetic patients with erectile dysfunction. BJU Int 83:66-70, 1999
68. Jevtich MJ, Edson M, Jarman WD, Herrera HH: Vascular factor in erectile failure among diabetics. Urology 19:163-168, 1982
69. McVary KT, Rathnau CH, McKenna KE: Sexual dysfunction in the diabetic BB/WOR rat: a role of central neuropathy. Am J Physiol 272:R259-R267, 1997
70. Rehman J, Chenven E, Brink P, Peterson B, Walcott B, Wen YP, Melman A, Christ G: Diminished neurogenic but not pharmacological erections in the 2- to 3-month experimentally diabetic F-344 rat. Am J Physiol 272:H1960-H1971, 1997
71. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF: Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res 11:123-132, 1999
72. Escrig A, Marin R, Abreu P, Gonzalez-Mora JL, Mas M: Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Reprod 66:185-189, 2002
73. Podlasek CA, Zelner DJ, Bervig TR, Gonzalez CM, McKenna KE, McVary KT: Characterization and localization of nitric oxide synthase isoforms in the BB/ WOR diabetic rat. J Urol 166:746-755, 2001
74. Cellek S, Foxwell NA, Moncada S: Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 52:2353-2362, 2003
75. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
76. Podlasek CA, Zelner DJ, Harris JD, Meroz CL, Tang Y, McKenna KE, McVary KT: Altered Sonic hedgehog signaling is associated with morphological abnormalities in the penis of the BB/WOR diabetic rat. Biol Reprod 69:816-827, 2003
77. Wingard CJ, Husain S, Williams J, James S: RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 285:R1145-R1152, 2003
78. Chang S, Hypolite JA, Changolkar A, Wem AJ, Chacko S, DiSanto ME: Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 15:53-62, 2003
79. Wingard CJ, Johnson JA, Holmes A, Prikosh A: Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 284: R1572-R1579, 2003
80. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM: Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 7:119-122, 2001
81. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, Graziottin A, Heiman J, Laan E, Leiblum S, Padma-Nathan H, Rosen R, Segraves K, Segraves RT, Shabsigh R, Sipski M, Wagner G, Whipple B: Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 163:888-893, 2000
82. Wincze JP, Albert A, Bansal S: Sexual arousal in diabetic females: physiological and self-report measures. Arch Sex Behav 22:587-601, 1993
83. Enzlin P, Mathieu C, Van den Bruel A, Bosteels J, Vanderschueren D, Demyttenaere K: Sexual dysfunction in women with type 1 diabetes: a controlled study. Diabetes Care 25:672-677, 2002
84. Schiel R, Muller UA: Prevalence of sexual disorders in a selection-free diabetic population (JEVIN). Diabetes Res Clin Pract 44:115-121, 1999
85. Munarriz R, Kim NN, Goldstein I, Traish AM: Biology of female sexual function. Urol Clin North Am 29:685-693, 2002
86. Hale TM, Heaton JP, Adams MA: A framework for the present and future development of experimental models of female sexual dysfunction. Int J Impot 15 (Suppl. 5):S75-S79, 2003
87. Bechara A, Bertolino MV, Casabe A, Munarriz R, Goldstein I, Morin A, Secin F, Literat B, Pesaresi M, Fredotovich N: Duplex Doppler ultrasound assessment of clitoral hemodynamics after topical administration of alprostadil in women with arousal and orgasmic disorders. J Sex Marital Ther 29 (Suppl. 1):1-10, 2003
88. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A: Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660-665, 2002
89. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682-688, 2000
90. Berman JR, Berman LA, Toler SM, Gill J, Haughie S: Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 170:2333-2338, 2003
91. Stapleton A: Urinary tract infections in patients with diabetes. Am J Med 113 (Suppl. 1A):80S-84S, 2002
92. Zhanel GG, Nicolle LE, Harding GK: Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus: the Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis 21:316-322, 1995
93. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter PK, Braveboer B, Collet TJ, Jansz AR, Hoepelman AM: Asymptomatic bacteriuria can be considered a diabetic complication in women with diabetes mellitus. Adv Exp Med Biol 485:309-314, 2000
94. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet JT, Schneeberger PM, Hoepelman AI: Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 161:1421-1427, 2001
95. Hooton TM, Scholes D, Stapleton AE, Roberts PL, Winter C, Gupta K, Samadpour M, Stamm WE: A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 343:992-997, 2000
96. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI: Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 23:1737-1741, 2000
97. Harding GK, Zhanel GG, Nicolle LE, Cheang M: Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 347:1576-1583, 2002
98. Boyko EJ, Fihn SD, Scholes D, Chen CL, Normand EH, Yarbro P: Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care 25:1778-1783, 2002
99. Fihn SD, Boyko EJ, Scholes D, Jackson S, Hu K, Abraham L, Gupta K: Diabetes and the risk of urinary tract infection in community dwelling, post-menopausal women (Abstract). In Urologic Complications of Diabetes. Bethesda, MD, National Institutes of Health, 2003, p. 29-30
100. Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B: Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 98:1045-1052, 2001
101. Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, Stapleton AE, Stergachis A, Stamm WE: A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 335:468-474, 1996
102. Fihn SD: Clinical practice: acute uncomplicated urinary tract infection in women. N Engl J Med 349:259-266, 2003
103. Hansen DS, Gottschau A, Kolmos HJ: Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect 38: 119-132, 1998
104. Stamm WE, Norrby SR: Urinary tract infections: disease panorama and challenges. J Infect Dis 183 (Suppl. 1):S1-S4, 2001
105. Wullt B, Bergsten G, Fischer H, Godaly G, Karpman D, Leijonhufvud I, Lundstedt AC, Samuelsson P, Samuelsson M, Svensson ML, Svanborg C: The host response to urinary tract infection. Infect Dis Clin North Am 17:279-301, 2003
106. Johnson JR: Microbial virulence determinants and the pathogenesis of urinary tract infection. Infect Dis Clin North Am 17:261-278, viii, 2003
107. Brauner A, Katouli M, Ostenson CG: P-fimbriation and haemolysin production are the most important virulence factors in diabetic patients with Escherichia coli bacteraemia: a multivariate statistical analysis of seven bacterial virulence factors. J Infect 31:27-31, 1995
108. Geerlings SE, Brouwer EC, Gaastra W, Stolk R, Diepersloot RJ, Hoepelman AI: Virulence factors of Escherichia coli isolated from urine of diabetic women with asymptomatic bacteriuria: correlation with clinical characteristics. Antonie Van Leeuwenhoek 80:119-127, 2001
109. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AI: Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care 25:1405-1409, 2002
110. Balasoiu D, van Kessel KC, van Kats-Renaud HJ, Collet TJ, Hoepelman AI: Granulocyte function in women with diabetes and asymptomatic bacteriuria. Diabetes Care 20:392-395, 1997
111. Zozulinska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B: Serum interleukin-8 level is increased in diabetic patients. Diabetologia 42:117-118, 1999
112. Geerlings SE, Hoepelman AI: Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26:259-265, 1999
113. Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI: Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 30:995-1001, 2000
114. Li YM, Tan AX, Vlassara H: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1:1057-1061, 1995
115. Huttner KM, Bevins CL: Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res 45:785-794, 1999
116. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T: Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 101:1633-1642, 1998
117. UK Prospective Diabetes Study (UK-PDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
118. Wan P, Lau J, Chalmore T: Meta-analysis of effects of intensive blood glucose control on the late diabetic complications of type 1 diabetes. Lancet 341:877-890, 1993